News Sentiment

ALXO sentiment intelligence

Alx Oncology Holdings news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 55 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.13 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

83/100 classification confidence.

Company focus 47

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend active

+2.7% over one week, +34.5% over four weeks, trend active, and below fair value.

Latest direct headline Neutral

ALX Oncology (ALXO) SVP sells 1,404 shares for RSU tax obligations

Market Reaction

Balanced read

65/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 83/100 classification
One-week reaction 2.7% Price confirming higher
Trend fit Trend active 34.5% over four weeks
Fair value -52.2% Below fair value
Market Dynamics buy signal Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 17
Neutral 35
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 47
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
TradingView 8
Market source 7
Stock Titan 7
TradingKey 6
simplywall.st 3
MarketBeat 3
The Manila Times 2
GlobeNewswire 2

Event Lens

What the news is about

Classified themes
Market update 34
Earnings 18
Balance sheet 1
Capital return 1
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-55 of 55
TradingKey Direct company coverage

ALX Oncology Holdings Inc (ALXO) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for ALX Oncology Holdings Inc (ALXO), noting its current earnings forecast score of 8.00 within the Biotechnology & Medical Research industry. Analysts have set an average price target of $3.00 for ALXO, with most recommending a "Buy" tr

Tone
Positive 66/100
Event
Earnings
Published
17 Jun 2026 03:11
Source
TradingKey
Stock Titan Direct company coverage

ALX Oncology (NASDAQ: ALXO) holders back board slate, executive pay and KPMG audit

ALX Oncology Holdings Inc. stockholders voted on June 10, 2026, to re-elect Class II directors Daniel Curran, Rekha Hemrajani, and Chris Takimoto, to serve until the 2029 annual meeting. Shareholders also approved the compensation of the company's named executive officers on an a

Tone
Neutral 50/100
Event
Market update
Published
11 Jun 2026 20:09
Source
Stock Titan
TradingView Direct company coverage

ALXO: All voting proposals passed and clinical programs advanced, with key data expected soon

ALX Oncology Holdings Inc. (ALXO) announced that all voting proposals, including director elections, executive compensation, and auditor ratification, were approved at their 2026 Annual General Meeting. The company also reported progress in its clinical programs, evorpacept and A

Tone
Positive 70/100
Event
Market update
Published
10 Jun 2026 20:39
Source
TradingView
Zacks Investment Research Direct company coverage

ALX Oncology Holdings (ALXO)

Tone
Neutral 50/100
Event
Market update
Published
22 Jul 2020 20:43
Source
Zacks Investment Research